| 1 |
35165514 | Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer. | 2022 |
1 |
| 2 |
32924987 | Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma. | 2021 |
1 |
| 3 |
33184874 | ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer. | 2021 Jun |
3 |
| 4 |
33288882 | Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. | 2021 Jan |
1 |
| 5 |
33431858 | ABCA8-mediated efflux of taurocholic acid contributes to gemcitabine insensitivity in human pancreatic cancer via the S1PR2-ERK pathway. | 2021 Jan 11 |
1 |
| 6 |
33662667 | Suppression of Wnt/β-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer. | 2021 Apr 16 |
3 |
| 7 |
33744388 | Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. | 2021 Jun 1 |
1 |
| 8 |
33878513 | CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells. | 2021 Jul |
1 |
| 9 |
34490236 | CIRBP Knockdown Attenuates Tumourigenesis and Improves the Chemosensitivity of Pancreatic Cancer via the Downregulation of DYRK1B. | 2021 |
1 |
| 10 |
32615164 | LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma. | 2020 |
1 |
| 11 |
30866697 | Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells. | 2019 |
1 |
| 12 |
31373074 | Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. | 2019 Nov |
1 |
| 13 |
31424641 | Anticancer effects of curzerenone against drug-resistant human lung carcinoma cells are mediated via programmed cell death, loss of mitochondrial membrane potential, ROS, and blocking the ERK/MAPK and NF-κB signaling pathway. | 2019 May-Jun |
1 |
| 14 |
31602254 | Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma. | 2019 |
1 |
| 15 |
29749405 | Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. | 2018 May 1 |
1 |
| 16 |
29848706 | Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells. | 2018 Jun |
2 |
| 17 |
29960845 | LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. | 2018 Jun |
1 |
| 18 |
30577630 | Gemcitabine Induces Microvesicle Particle Release in a Platelet-Activating Factor-Receptor-Dependent Manner via Modulation of the MAPK Pathway in Pancreatic Cancer Cells. | 2018 Dec 21 |
1 |
| 19 |
30662800 | Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer. | 2018 |
2 |
| 20 |
28720574 | Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction. | 2017 Aug 15 |
1 |
| 21 |
28797284 | Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). | 2017 Aug 10 |
2 |
| 22 |
29069735 | HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation. | 2017 Sep 22 |
6 |
| 23 |
27384485 | Inhibition of ERα/ERK/P62 cascades induces "autophagic switch" in the estrogen receptor-positive breast cancer cells exposed to gemcitabine. | 2016 Jul 26 |
2 |
| 24 |
25946136 | Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy. | 2015 |
1 |
| 25 |
23091117 | Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. | 2013 Jan 1 |
2 |
| 26 |
23320839 | MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. | 2013 Jan 15 |
1 |
| 27 |
21277645 | ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. | 2011 Sep |
3 |
| 28 |
21529991 | Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. | 2011 Nov |
1 |
| 29 |
22110196 | Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide. | 2011 Nov |
1 |
| 30 |
20726858 | Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. | 2010 Nov |
2 |
| 31 |
16818479 | Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. | 2006 Jun |
2 |
| 32 |
17054996 | Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. | 2006 Dec |
1 |
| 33 |
15073105 | Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. | 2004 Apr 1 |
1 |
| 34 |
15476743 | Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. | 2004 Oct 19 |
5 |
| 35 |
11278435 | Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. | 2001 May 4 |
2 |